BICYCLE THERAPEUTICS PLC-ADR (BCYC)
US0887861088 - ADR
BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q1 2024
BCYC stock results show that Bicycle Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
BCYC Crosses Above Key Moving Average Level
Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day
Bicycle Therapeutics to Host R&D Day on December 14
Oversold Conditions For Bicycle Therapeutics (BCYC)
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
Seagen, Astellas post Phase 3 win for bladder cancer therapy (NASDAQ:SGEN)
In a recent Phase 3 clinical trial, Seagen's (SGEN) bladder cancer drug Padcev, in combination with Merck's (MRK) Keytruda, achieved positive outcomes. Read more here.
Bicycle Therapeutics Enters Oversold Territory (BCYC)
Bicycle Therapeutics updates on bladder cancer therapy
Bicycle Therapeutics (BCYC) traded higher Monday after announcing that the FDA agreed on a Phase 2/3 pivotal trial for its bladder cancer therapy BT8009. Read more here.
Why Shares of Bicycle Therapeutics Were Rising on Monday
The company said it is working with the FDA to structure a phase 2/3 trial for its bladder cancer therapy.
Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer
Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
(NASDAQ:BCYC)
Bicycle Therapeutics press release (BCYC): Q2 GAAP EPS of -$1.41 misses by $0.39.Revenue of $11.4M (+160.3% Y/Y) misses by $1.52M.Cash and cash equivalents were $340.4 million as...
Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Why Bicycle Therapeutics Stock Raced Ahead Today
The company's latest attempt at capital raising seems to be having enviable success.